XML 67 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8
Benefit Plans (Tables)
3 Months Ended
Dec. 28, 2013
Restricted Stock Activity

A summary of the Company’s RSU activity and related information for the three months ended December 28, 2013, is as follows:

 

                                                                          
     Number of
RSUs

(in thousands)
    Weighted-
Average
Grant Date
Fair Value
     Aggregate
Intrinsic
Value

(in millions)
 

Balance at September 28, 2013

     13,326      $ 435.70      

RSUs granted

     6,183      $ 491.93      

RSUs vested

     (2,256   $ 379.23      

RSUs cancelled

     (216   $ 461.35      
  

 

 

      

Balance at December 28, 2013

     17,037      $ 463.23       $ 9,543   
  

 

 

      
Stock Option and Related Information

A summary of the Company’s stock option activity and related information for the three months ended December 28, 2013, is as follows:

 

                                                                                                   
     Outstanding Options  
     Number
of Options
(in thousands)
    Weighted-
Average
Exercise
Price
     Weighted-
Average
Remaining
Contractual

Term
(in years)
     Aggregate
Intrinsic
Value

(in millions)
 

Balance at September 28, 2013

     4,094      $ 139.65         

Options granted

     1      $ 66.26         

Options exercised

     (1,308   $ 102.86         
  

 

 

         

Balance at December 28, 2013

     2,787      $ 156.89         1.2       $ 1,124   
  

 

 

         

Exercisable at December 28, 2013

     2,768      $ 157.56         1.1       $ 1,114   

Expected to vest after December 28, 2013

     19      $ 58.03         7.6       $ 10   
Summary of Share-Based Compensation Expense

The following table shows a summary of the share-based compensation expense included in the Condensed Consolidated Statements of Operations for the three months ended December 28, 2013 and December 29, 2012 (in millions):

 

                                                 
     Three Months Ended  
     December 28,
2013
     December 29,
2012
 

Cost of sales

   $ 109       $ 85   

Research and development

     289         224   

Selling, general and administrative

     283         236   
  

 

 

    

 

 

 

Total share-based compensation expense

   $ 681       $ 545